Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Inventories : €338.0 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Total Inventories?

Laboratorios Farmaceuticos Rovi's total inventories for the quarter that ended in Mar. 2024 was €338.0 Mil. Laboratorios Farmaceuticos Rovi's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was €338.0 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Laboratorios Farmaceuticos Rovi's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was €0.42.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Laboratorios Farmaceuticos Rovi's Days Inventory for the three months ended in Mar. 2024 was 470.80.

Inventory Turnover measures how fast the company turns over its inventory within a year. Laboratorios Farmaceuticos Rovi's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.19.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Laboratorios Farmaceuticos Rovi's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 2.24.

Laboratorios Farmaceuticos Rovi Total Inventories Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Total Inventories Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

158.81

227.20

245.47

311.94

337.97

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															327.06	351.40	365.68	337.97	337.97

Laboratorios Farmaceuticos Rovi Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Laboratorios Farmaceuticos Rovi's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(13.085	+	0.75 * 131.488	+	0.5 * 337.971	-	254.881
-	0	-	4.105)	/	51.3154
=	0.42

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Laboratorios Farmaceuticos Rovi's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	337.9695	/	65.505	*	365 / 4
	=	470.80

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Laboratorios Farmaceuticos Rovi's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	65.505	/	337.9695
	=	0.19

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Laboratorios Farmaceuticos Rovi's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	337.9695	/	151.175
	=	2.24

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Laboratorios Farmaceuticos Rovi Total Inventories Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.